[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-parkinsonism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-parkinsonism":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100622622","etiology-phenotype-outcome-pathway-study-on-freezing-of-gait-fog-100622622",false,"NCT07386015","Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)","FREEZE-Path Cohort: Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)","Inclusion Criteria:\n\n1. Age 30-85 years\n2. Presence of freezing of gait or non-freezing gait or balance impairment\n3. Diagnosis of Parkinson's disease or related parkinsonian disorders according to established international criteria (including PD, PSP, MSA, DLB, CBD, vascular parkinsonism, or idiopathic normal pressure hydrocephalus)\n4. Ability to complete gait and balance assessment tasks independently or with assistance\n5. Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n1. Severe dementia (Mini-Mental State Examination score \\\u003C 10)\n2. Severe psychiatric disorders interfering with study participation\n3. Severe cardiopulmonary, musculoskeletal, or other medical conditions significantly affecting gait safety\n4. Stroke, fracture, or other major medical events within the past 3 months\n5. Inability to comply with follow-up procedures\n6. Refusal of video or speech data collection","ALL","30 Years","85 Years",{"count":20,"type":21},700,"ESTIMATED","36 Months","OBSERVATIONAL","This study is a prospective, multicenter, observational cohort (patient registry) designed to better understand freezing of gait (FOG), a disabling walking problem that can occur in Parkinson's disease and other related neurological conditions.The purpose of this registry is to collect long-term clinical information from patients with freezing of gait or gait and balance problems, and to explore how different causes of FOG are related to symptoms, walking patterns, falls, disease progression, and outcomes over time. The study will include participants with Parkinson's disease and other conditions associated with freezing of gait.Participants will receive standard medical care as determined by their treating physicians. No experimental drugs or study-related treatments will be assigned as part of this registry. Clinical information will be collected during routine visits and follow-up assessments, including questionnaires, walking and balance evaluations, video recordings, and other commonly used clinical tests.The information collected in this study may help improve the understanding of freezing of gait, support better risk assessment for falls, and guide future research and clinical management strategies for patients with gait and balance disorders.",[26,27,28,29,30],"Freezing of Gait","Parkinson's Disease","Parkinsonism","Vascular Parkinsonism","Idiopathic Normal Pressure Hydrocephalus (INPH)",[26,27,32],"parkinsonism","RECRUITING","2026-03-08",{"date":36,"type":37},"2026-03-10","ACTUAL",{"date":39,"type":37},"2026-02-28",{"date":41,"type":21},"2030-11-30",{"name":43,"class":44},"Tianjin Huanhu Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100589088","ai-enhanced-optimization-of-acute-levodopa-challenge-test-100589088","NCT06949865","AI-Enhanced Optimization of Acute Levodopa Challenge Test","Clinical Research on Optimization of Acute Levodopa Challenge Test and Exploration of New Motor Paradigm Based on the Integration of Perception Technology and Artificial Intelligence","Inclusion Criteria:\n\n1. Parkinson's disease (PD) group: 1. Patients with confirmed Parkinson's disease diagnosed based on the 2015 International Movement Disorder Society (MDS) Parkinson's Disease Diagnostic Criteria; 2. Patients with early-stage PD meet the Hoehn-Yahr score ≤ 2.5 points, and patients with intermediate and advanced PD meet the Hoehn-Yahr score of 2.5-5 points; 3. Subjects are 50-75 years old (including boundary values), gender is not limited; 4. Agree to undergo study-related examination evaluation and sign informed consent.\n2. Multiple system atrophy (MSA) group : 1. Patients with confirmed or probable MSA diagnosed based on the diagnostic criteria for MSA published by the International Movement Disorder Society (MDS) in 2022 ;2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n3. Progressive supranuclear palsy (PSP) group: 1. Patients with confirmed or probable PSP diagnosed based on the diagnostic criteria of the 2017 International Movement Disorder Association PSP Collaborative Group; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n4. Vascular parkinsonism (VP) group: 1. In line with the diagnostic recommendations of vascular parkinsonism in accordance with the 2004 International Association for Movement Disorders and the 2017 Chinese expert consensus; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n5. Drug-induced parkinsonism (DIP) group: 1. Parkinsonism; 2. Drug history, the appearance of symptoms is related to specific drugs; 3. Symptoms are reversible, and the symptoms are reduced or disappeared when the corresponding drugs are reduced; 4. Rule out other causes; 5. Subjects are 50-75 years old (including boundary values), gender is not limited; 6. Agree to undergo study-related examination evaluation and sign informed consent.\n6. Corticobasal degeneration (CBD) group: 1. Diagnosis of probable or probable CBD based on the 2019 Chinese diagnostic criteria for corticobasal degeneration; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n7. Dementia with Lewy Bodies (DLB) Group: 1. Diagnosed as probable or possible DLB based on the 2017 international DLB diagnostic criteria and the 2021 Chinese DLB diagnostic criteria. 2. Exhibits symptoms of Parkinsonism. 3. Subjects are aged 50-75 years (inclusive), with no gender restriction. 4. Agree to undergo study-related assessments and evaluations and signs the informed consent form.\n\nExclusion Criteria:\n\n1. Cognitive dysfunction, unable to complete the study (MMSE \\\u003C 23)\n2. Inability to tolerate levodopa shock test\n3. Patients with failure of important organs (heart, lung, liver, kidney, etc.), malignant tumors, unstable conditions and other serious internal diseases\n4. Those with serious behavioral problems or mental disorders\n5. Inability to sign informed consent\n6. Other conditions that are considered unsuitable by the investigator to participate in this study.","50 Years","75 Years",{"count":56,"type":21},2000,"A quantitative evaluation method was developed for Parkinson's disease and other atypical parkinonism by integrating an innovative motor paradigm with perception technologies and artificial intelligence. Combined with traditional motor paradigms and the acute levodopa challenge test, this study aims to identify diagnostic cut-off values for PD and other atypical parkinonism, explore digital biomarkers for early and differential diagnosis, and establish a corresponding diagnostic model.",[29,59,60,61,62,63,64],"Drug-induced Parkinsonism","Corticobasal Degeneration (CBD)","Parkinson Disease (PD)","Dementia With Lewy Body Disease","Progressive Supranuclear Palsy(PSP)","Multiple System Atrophy (MSA)","2025-04-22",{"date":67,"type":37},"2025-04-29",{"date":69,"type":37},"2024-05-28",{"date":71,"type":21},"2026-12-31",{"name":73,"class":44},"Beijing Tiantan Hospital",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":96,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":45},"100529528","the-use-of-the-cue1cue1-in-people-with-parkinsons-disease-and-related-disorders-100529528","NCT06174948","The Use of the CUE1\u002FCUE1+ in People With Parkinson's Disease and Related Disorders","The Use of the CUE1\u002FCUE1+ Device in People With Idiopathic Parkinson's Disease and Related Disorders: A Feasibility Study","Inclusion Criteria:\n\n* Adults over 18 years old\n* Clinical diagnosis of idiopathic PD and related disorders including progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and vascular Parkinsonism (VaP) as well as atypical dystonias and tremor disorders and Orthostatic Tremor (OT)\n* willing to participate and written consent provided after read the participant information sheet.\n\nExclusion Criteria:\n\nIndividuals with:\n\n* other neurological disorders excluding idiopathic PD, related disorders such PSP, MSA, CBD, and VaP as well as atypical dystonias and tremor disorders, affecting movement, balance and gait\n* metabolic or autoimmune disorders affecting movement, balance and gait\n* acute orthopaedic disorders influencing balance control and gait\n* audiovestibular disorders including severe hearing loss\n* visual disturbances, poor eyesight\n* not able to provide written consent form to participate\n* clinical diagnosis of cognitive impairment including dementia or Alzheimer's.\n* Mental impairments (illusions, hallucinations, impulse control disorders) (self-reported)\n\nTechnical contraindications related to CUE1 device:\n\n* implanted metallic or electronic devices usage\n* hypersensitivity to vibrotactile stimulation\n* skin conditions and\u002For open wound in the area of where the device will be positioned (e.g., sternum) if taking medicines for PD or related disorder, then on stable dose of treatment for the last three months.","18 Years",{"count":83,"type":21},70,"INTERVENTIONAL",[86],"NA","People with Parkinson's disease (PD) commonly experience a range of both motor (e.g., bradykinesia, rigidity, tremor, and postural instability) and non-motor (e.g., fatigue, psychiatric and behavioural disturbances, autonomic dysfunction, cognitive impairment, sleep dysfunction and olfactory loss) features. Currently, it is challenging to alleviate these symptoms with first-line treatment, the medications such as levodopa. The CUE1 is a non-invasive device, which is approved for sale in the UK market as a Class I low risk device. It is worn on the sternum or other part of the body such as the forearm and attaches to the skin via an adhesive patch which has been dermatologically tested and approved.\n\nThe CUE1 delivers pulsing cueing and vibrotactile stimulation to help improve symptoms in people with PD and it has shown to be effective in doing so in previous small case studies. This 9-week feasibility study aims to investigate the feasibility, safety, tolerability and effect of using the CUE1 as an intervention to improve motor and non-motor symptoms in people with PD and related movement disorders. People with clinical diagnosis of idiopathic PD and related disorders including those with progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, orthostatic tremor and vascular Parkinsonism as well as atypical dystonias and tremor disorders aged over 18 years old who have the capacity to provide a written consent form to take part in the study, will receive as intervention to wear the CUE1 device at home, on daily basis while carrying out their activities of daily living. Participants will also have to attend face-to-face appointments of approximately half a day, to discuss how they are getting on with using the CUE1 and complete questionnaires on their symptoms, walking, balance, and movement tests as well as a participant's clinical diary.",[89,90,91,92,93,94,29,95],"Parkinson's Disease and Parkinsonism","Progressive Supranuclear Palsy","Different Types of Tremor Including Essential Tremor","Dystonia","Multiple System Atrophy","Corticobasal Degeneration","Orthostatic Tremor",[97],"CUE1, Parkinson's disease, movement disorders","2024-11-18",{"date":100,"type":37},"2024-11-21",{"date":102,"type":37},"2024-03-25",{"date":104,"type":21},"2025-03-31",{"name":106,"class":44},"Queen Mary University of London"]